A Phase 2 interventional study of AK111 and Placebo in Ankylosing Spondylitis, sponsored by Akeso. Completed at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-06.
Sponsored by Akeso · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.
Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 36th largest by enrollment of the 62 interventional ones that give a count, is one of 8 that started in 2021, is one of 11 in phase 2, and was the 44th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:
China-Japan Friendship Hospital · Sites in China
Ages 18–75
China-Japan Friendship Hospital · Sites in China
Ages 18–75
Huabo Biopharm Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 18–70
China-Japan Friendship Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 22 · Phase 4 17
First in 2005; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 150 across the 62 interventional studies, 440 across the 14 observational. Of the 42 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 76 have an industry lead sponsor. The 10 most frequent:
Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Akeso has 2 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
9 of the studies in Spondylitis, Ankylosing with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07237568Phase 3Lynk Pharmaceuticals Co., LtdA Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis | 2026-11 |
| NCT06000956Phase 3Tasly Pharmaceutical Group Co., LtdA Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo | 2026-12-01 |
| NCT07261644Phase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | 2027-01-14 |
| NCT07172360Phase 3Jiangsu vcare pharmaceutical technology co., LTDEfficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. | 2027-08-30 |
| NCT07920861Huabo Biopharm Co., Ltd.A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 76 studies in Spondylitis, Ankylosing with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis.
The purpose of this study is to evaluate the efficacy and safety of AK111 in the treatment of subjects with active ankylosing spondylitis. Subjects will be randomized to receive AK111 or placebo following subcutaneous injection. The study period for each subject will be 25 weeks, including a screening period of up to 35 days, followed by a treatment period of 12 weeks and a follow up period of 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AK111 75mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
Biological: AK111
AK111 150mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
Biological: AK111
AK111 300mg will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
Biological: AK111
Placebo will be administered by subcutaneous injection at Week 0, 1 and 4 , followed by dosing every 4 weeks until Week12.
Biological: Placebo
AK111 administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
Placebo administered subcutaneously at Week 0, 1, and 4, then every 4 weeks
Percentage of subjects who achieve Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response at Week 16.
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global, pain, function (assessed by BASFI) and inflammation (mean of Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 5 and 6 ). ASAS20 response is defined as improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≥1 unit in the remaining domain.
Time frame: Week16
Percentage of subjects with treatment-emergent adverse events (TEAEs) during the study.
Time frame: Baseline to Week20
Percentage of subjects with treatment-emergent serious adverse events (SAEs) during the study.
Time frame: Baseline to Week20
Percentage of subjects who achieve SpondyloArthritis International Society 40% improvement (ASAS40) response at Week 16.
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global, pain, function (assessed by BASFI) and inflammation (mean of Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 5 and 6 ). ASAS40 response is defined as improvement of ≥40% and ≥2 units in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening in the remaining domain.
Time frame: Week 16
Percentage of subjects who achieve ASAS20 response at each visit from baseline.
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global, pain, function (assessed by BASFI) and inflammation (mean of Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 5 and 6 ). ASAS20 response is defined as improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≥1 unit in the remaining domain.
Time frame: Baseline to Week 20
Percentage of subjects who achieve ASAS40 at each visit from baseline.
ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global, pain, function (assessed by BASFI) and inflammation (mean of Ankylosing Spondylitis Disease Activity Index \[BASDAI\] question 5 and 6 ). ASAS40 response is defined as improvement of ≥40% and ≥2 units in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening in the remaining domain.
Time frame: Baseline to Week 20
Change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at each visit from baseline.
The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) . The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL.
Time frame: Baseline to Week 20
pharmacodynamics(PD) parameters: Changes of Interleukin-17A (IL-17A) level in peripheral serum compared with baseline and its relationship with AK111 exposure.
Time frame: Baseline to Week 20
Immunogenicity: Number and percentage of subjects with detectable anti-AK111 antibody (ADA).
Time frame: Baseline to Week 20
Change from baseline on the 36-item Short-Form (SF-36) Health Survey at each visit from baseline.
The SF-36 is a 36-item generic health status measure. It measures 8 general health domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. Each of the 8 domain scores and the component summary scores range from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline to Week 20
Area under the curve from 0 to the time of the last quantifiable concentration (AUC0-t)
Time frame: Baseline to Week 20
Maximum observed concentration (Cmax)
Time frame: Baseline to Week 20
Terminal elimination half-life (T1/2)
Time frame: Baseline to Week 20
Time of occurrence of Cmax (Tmax)
Time frame: Baseline to Week 20
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Apr 2022, 10 months.
Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gumokimab